Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 3/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | AOC1 | P19801 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513006 | 0.85 | APP (0.43) | CACNA1CSCN5AKCNH2APPCXCR4 | |
| SCHEMBL12895814 | 0.84 | CACNA1C (0.56) | CACNA1CSCN5AKCNH2APPHSD11B1 | |
| SCHEMBL14518469 | 0.81 | SCN5A (0.66) | CACNA1CSCN5AKCNH2HSD11B1GRM5 | |
| SCHEMBL20436538 | 0.81 | CACNA1C (0.49) | CACNA1CSCN5AKCNH2APPHSD11B1 | |
| SCHEMBL5631959 | 0.80 | APP (0.47) | SCN5AKCNH2APPNCF1AOC1 | |
| SCHEMBL29907615 | 0.80 | APP (0.47) | SCN5AKCNH2APPNCF1AOC1 | |
| SCHEMBL1040083 | 0.79 | KCNH2 (0.47) | CACNA1CSCN5AKCNH2APPHSD11B1 | |
| SCHEMBL22388250 | 0.78 | CACNA1C (0.46) | CACNA1CSCN5AKCNH2APPHSD11B1 | |
| SCHEMBL7040754 | 0.78 | KCNH2 (0.46) | CACNA1CSCN5AKCNH2APPHSD11B1 | |
| SCHEMBL18160808 | 0.77 | NCF1 (0.36) | CACNA1CSCN5AKCNH2APPNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| CN-1209060-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | CACNA1C 929/4885SCN5A 1523/4885KCNH2 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.